News headlines about Relypsa (NASDAQ:RLYP) have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Relypsa earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.5231172151877 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
TRADEMARK VIOLATION WARNING: This report was published by BNB Daily and is the property of of BNB Daily. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/relypsa-rlyp-given-news-sentiment-score-of-0-14-updated-updated-updated.html.
Relypsa, Inc is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company’s technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address.
Receive News & Ratings for Relypsa Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc and related companies with MarketBeat.com's FREE daily email newsletter.